DocMorris AG (SWX:DOCM)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 338.91M |
| Revenue (ttm) | 1.12B |
| Net Income (ttm) | -134.40M |
| Shares Out | 48.11M |
| EPS (ttm) | -3.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,690 |
| Average Volume | 379,220 |
| Open | 6.99 |
| Previous Close | 7.00 |
| Day's Range | 6.90 - 7.11 |
| 52-Week Range | 3.92 - 24.90 |
| Beta | 1.63 |
| RSI | 73.02 |
| Earnings Date | Aug 19, 2026 |
About DocMorris AG
DocMorris AG operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally. The company offers prescription and over-the-counter medicines, and consumer health products, as well as beauty and personal care products, nutritional supplements, painkillers, and first aid products. The company also provides professional health care services to doctors, pharmacies, insurers, and health institutions. It sells its products to online mail-order pharmacies, and private individuals under the DocMorris, PromoFarma ... [Read more]
Financial Performance
In 2025, DocMorris AG's revenue was 1.12 billion, an increase of 10.56% compared to the previous year's 1.02 billion. Losses were -134.40 million, 38.2% more than in 2024.
Financial StatementsNews
DocMorris AG Earnings Call Transcript: Q1 2026
Revenue grew 10.7% year-over-year, led by 30.4% Rx and 63.1% digital services growth. Adjusted EBITDA improved by CHF 9.8 million to CHF -6.3 million, with breakeven targeted in 2026. Guidance for revenue and EBITDA is confirmed, with strong momentum in all key segments.
DocMorris AG Earnings Call Transcript: H2 2025
Revenue grew 11.1% in 2025, driven by Rx (+33%) and digital services (+110%), with strong margin gains and a robust liquidity position. EBITDA breakeven is targeted for 2026, supported by operational efficiencies, digital expansion, and a new Google partnership.
DocMorris AG Earnings Call Transcript: H1 2025
Strong Rx and TeleClinic growth drove a 10.2% revenue increase in H1 2025, with gross margin up 70 bps and a solid balance sheet after a CHF 200 million capital raise. Full-year guidance is confirmed, with sequential EBITDA improvement expected as marketing spend is optimized.
DocMorris AG Earnings Call Transcript: Q1 2025
Q1 2025 saw 13% revenue growth, with Rx up 52% and TeleClinic revenue more than doubling. A CHF 200 million capital raise is fully underwritten to fund growth, with EBITDA break-even targeted in 2026 and positive free cash flow in 2027.
DocMorris AG Earnings Call Transcript: H2 2024
Revenue grew 7% year-over-year, with all segments contributing and non-Rx business reaching profitability. Teleclinic doubled revenues, and a CHF 200 million capital raise is planned to support Rx growth and refinance debt. Guidance will be updated post-Q1 results.
DocMorris AG Earnings Call Transcript: H1 2024
Breakeven achieved in the base business, with strong eRX growth following CardLink's launch and TeleClinic doubling sales. 2024 revenue is guided to grow 5–10%, with increased investment in eRX customer acquisition impacting EBITDA, but long-term profitability targets remain intact.
DocMorris AG Earnings Call Transcript: H2 2023
Online drug retailer DocMorris meets expectations as cost savings help
Swiss online drug retailer DocMorris met expectations on Thursday as it released its full-year results for 2023, helped by structural cost savings.
Online drug retailer DocMorris trims top end of 2023 outlook
Swiss online drug retailer DocMorris on Thursday narrowed down the higher end of its annual core loss forecast, citing weaker development in the paper prescription business.